ArticleCancer cell international2025
Single-cell transcriptome analysis reveals regulatory programs of prognosis-associated RNA binding proteins during LIHC development.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pan-cancer analysis identifies KANSL2 as a cell-cycle-associated regulator of tumor progression and immunity in liver hepatocellular carcinoma.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC), a highly aggressive primary liver cancer, exhibits unclear heterogeneity in RNA-binding protein (RBP) expression dynamics. This study investigates single-cell-level RBP heterogeneity, regulatory roles in HCC progression, and their therapeutic potential.
methodsUtilizing TCGA-LIHC data, prognosis-associated RBPs were screened by univariate Cox analysis. Tumor clusters stratified via NMF algorithm underwent differential gene expression profiling and functional enrichment (GO/KEGG). Single-cell RNA sequencing dissected RBP heterogeneity in malignant and myeloid-derived cell populations, exploring intercellular interactions. Key RBP gene HDGF was functionally validated through in vitro assays (CCK-8, EdU, Transwell). SpliceSeq analysis revealed HDGF-mediated alternative splicing events in HCC.
resultsRBP expression correlated significantly with HCC histological/diagnostic grades. Prognostic RBPs, enriched in ribosome biogenesis and rRNA processing pathways, were upregulated in specific cell clusters. Single-cell analysis revealed distinct RBP expression patterns between primary and early recurrent HCCs, nominating YRDC and HDGF as putative regulators. Myeloid-derived cell populations exhibited unique RBP profiles, suggesting crosstalk with malignant cells during HCC progression. In vitro assays suggested that HDGF may contribute to enhanced proliferation, migration, and invasion of HCC cells, whereas its knockdown attenuated these phenotypes. GO/KEGG analysis implicated HDGF in survival-associated alternative splicing events, supported by TCGA SpliceSeq data.
conclusionRBPs display single-cell-level heterogeneity and are associated with pathways relevant to HCC progression. HDGF is identified as a candidate oncogenic RBP based on in vitro phenotypes and correlative splicing analyses. These findings highlight the potential of RBPs, including HDGF, as candidates for further mechanistic and therapeutic exploration in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.